- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/12 - Drugs for disorders of the metabolism for electrolyte homeostasis
Patent holdings for IPC class A61P 3/12
Total number of patents in this class: 299
10-year publication summary
|
11
|
16
|
17
|
21
|
26
|
35
|
14
|
15
|
18
|
11
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Vifor (International) AG | 144 |
10 |
| Ardelyx, Inc. | 119 |
9 |
| Renibus Therapeutics, Inc. | 68 |
8 |
| Daiichi Sankyo Company, Limited | 1891 |
6 |
| Société des Produits Nestlé S.A. | 10042 |
5 |
| Banyu Pharmaceutical Co., Ltd. | 40 |
5 |
| MSD K.K. | 65 |
5 |
| Beachbody, LLC | 617 |
4 |
| Protagonist Therapeutics, Inc. | 154 |
4 |
| AstraZeneca AB | 2824 |
3 |
| Baxter International Inc. | 1887 |
3 |
| Baxter Healthcare S.A. | 1393 |
3 |
| Takeda Pharmaceutical Company Limited | 2700 |
3 |
| University of Florida Research Foundation, Inc. | 4188 |
3 |
| Chugai Seiyaku Kabushiki Kaisha | 1423 |
3 |
| Kowa Company, Ltd. | 1241 |
3 |
| Shenzhen Salubris Pharmaceuticals Co., Ltd | 131 |
3 |
| Tricida, Inc. | 28 |
3 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 392 |
3 |
| Amilyfe, LLC | 65 |
3 |
| Other owners | 210 |